Latest news | Leukaemia Foundation - Page 2

Latest news

Hair recycling partnership shaving environment while tackling blood cancer

Friday, 01 March 2019

 

Social enterprise Sustainable Salons is once again throwing its support behind the Leukaemia Foundation’s World’s Greatest Shave by recycling hundreds of kilograms of hair to be donated for wigs and environmental hair booms thanks to Australia’s brave shavers.

For the second year running, Sustainable Salons are uniting

Breakthrough chronic lymphocytic leukaemia (CLL) treatment now available for Australians 

Monday, 25 February 2019

 

The Leukaemia Foundation welcomes the Federal Government’s announcement that the targeted cancer treatment Venetoclax (Venclexta®), will be added to Pharmaceutical Benefits Scheme (PBS) from 1 March 2019. 

Venetoclax will be available in combination with rituximab for patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia

VOLUNTEER RECEIVES OAM FOR 30 YEARS SERVICE TO CHARITIES AND FOUNDATIONS

Wednesday, 30 January 2019

 

Warwick local and Leukaemia Foundation volunteer, Elaine Stewart was recognised for her vital service and support of Australians living with blood cancer. 

Elaine Stewart was awarded an Order of Australia Medal for her selfless work and contribution to the Leukaemia Foundation’s Warwick Branch, as well as her local School’s Chaplaincy Committee and the Riding for the Disabled Association. 

A volunteer for more than

Blood cancer patient needs could go unmet as incidence rates rise

Monday, 14 January 2018,

 

The number of Australians living with a blood cancer is expected to rise around 30 per cent over the next decade, according to new Leukaemia Foundation analysis as it launches World’s Greatest Shave this week.

Currently 12,800 Australians are diagnosed with a blood cancer like leukaemia, lymphoma and myeloma every

Therapeutic Goods Administration (TGA) has today approved the use of the first CAR-T therapy in Australia

Therapeutic Goods Administration (TGA) has today approved the use of the first CAR-T therapy in Australia.  

A revolutionary cancer therapy that supercharges a patient’s immune cells to hunt and destroy cancer cells has been approved for use in Australia, ushering in a new era in medicine. 

The TGA has

Leukaemia Foundation receives HONcode certification

Friday, 07 December 2018

The Leukaemia Foundation has been granted prestigious HONcode certification for its high standard of reliable, ethical and trustworthy health and medical content featured throughout its digital communications platforms.

The HONcode is an international standard for health and medical websites issued by the Health on the Net Foundation,

Researchers at the Peter MacCallum Cancer Centre in Melbourne believe a new combination therapy for mantle cell lymphoma could lead to a cure in almost 100 per cent of cases.

Wednesday, 05 December 2018

 

A story in the Sydney Morning Herald recently reported Australian researchers were closing in on a cure for the disease which was considered a “death sentence” as little as three years ago.

Peter MacCallum Cancer Centre Professor Sarah-Jane Dawson said dozens of people living with mantle

New PBS listing vital to Australians living with Acute Myeloid Leukaemia

Friday, 30 November 2018

 

Leukaemia Foundation CEO Mr Bill Petch has today supported the Health Minister Mr Greg Hunt’s Pharmaceuticals Benefits Scheme (PBS) listing announcement of midostaurin (Rydapt®), a targeted therapy that is considered to be an important advancement in the treatment of Acute Myeloid Leukaemia (AML) in 25 years.

Mr

Leukaemia Foundation and HSANZ Jointly Funds Three PhD Investigators

Thursday, 8 November 2018

 

The Leukaemia Foundation and the Haematology Society of Australia and New Zealand (HSANZ) are proud to announce the co-funding of three Australian Clinical and Science PhD investigators, whose work will focus on understanding blood cancer biology and the development of new diagnostics and precision medicines.

“It is

Position Statement: Glyphosate

Monday, 22 October 2018

 

In August 2018, a landmark US court case against Monsanto, the manufacturer of weed killer Roundup, ruled a chemical used in the product (glyphosate) was a substantial factor in causing a school ground keeper’s terminal cancer and that the company had failed to warn of the

Share this page

X
X